company background image
ATRI

AtrionNasdaqGS:ATRI Stock Report

Market Cap

US$1.3b

7D

4.0%

1Y

13.0%

Updated

26 Oct, 2021

Data

Company Financials
ATRI fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends3/6

ATRI Overview

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Germany, and internationally.

Rewards

PE ratio (41x) is below the Medical Equipment industry average (49.9x)

Risk Analysis

No risks detected for ATRI from our risk checks.

Atrion Competitors

Dätwyler Holding

SWX:DAE

CHF6.2b

Price History & Performance

Summary of all time highs, changes and price drops for Atrion
Historical stock prices
Current Share PriceUS$713.49
52 Week HighUS$567.00
52 Week LowUS$783.84
Beta0.076
1 Month Change4.90%
3 Month Change14.12%
1 Year Change13.04%
3 Year Change4.45%
5 Year Change63.42%
Change since IPO9,520.09%

Recent News & Updates

Shareholder Returns

ATRIUS Medical EquipmentUS Market
7D4.0%3.6%1.9%
1Y13.0%23.8%33.4%

Return vs Industry: ATRI underperformed the US Medical Equipment industry which returned 23.1% over the past year.

Return vs Market: ATRI underperformed the US Market which returned 30.3% over the past year.

Price Volatility

Is ATRI's price volatile compared to industry and market?
ATRI volatility
ATRI Beta0.076
Industry Beta0.88
Market Beta1

Stable Share Price: ATRI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: ATRI's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1944636David Battathttps://www.atrioncorp.com

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Germany, and internationally. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. The company’s cardiovascular products comprise Myocardial Protection System that delivers fluids and medications, mixes critical drugs, controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery.

Atrion Fundamentals Summary

How do Atrion's earnings and revenue compare to its market cap?
ATRI fundamental statistics
Market CapUS$1.28b
Earnings (TTM)US$31.26m
Revenue (TTM)US$147.89m

41.1x

P/E Ratio

8.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ATRI income statement (TTM)
RevenueUS$147.89m
Cost of RevenueUS$84.86m
Gross ProfitUS$63.03m
ExpensesUS$31.77m
EarningsUS$31.26m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)17.36
Gross Margin42.62%
Net Profit Margin21.14%
Debt/Equity Ratio0.0%

How did ATRI perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

41%

Payout Ratio

Valuation

Is Atrion undervalued compared to its fair value and its price relative to the market?

41.09x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: ATRI ($711.8) is trading above our estimate of fair value ($201.96)

Significantly Below Fair Value: ATRI is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: ATRI is good value based on its PE Ratio (41x) compared to the US Medical Equipment industry average (49.9x).

PE vs Market: ATRI is poor value based on its PE Ratio (41x) compared to the US market (18.2x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ATRI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ATRI is overvalued based on its PB Ratio (5.3x) compared to the US Medical Equipment industry average (4.3x).


Future Growth

How is Atrion forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

15.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Atrion has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Atrion performed over the past 5 years?

2.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ATRI has high quality earnings.

Growing Profit Margin: ATRI's current net profit margins (21.1%) are lower than last year (22.7%).


Past Earnings Growth Analysis

Earnings Trend: ATRI's earnings have grown by 2.2% per year over the past 5 years.

Accelerating Growth: ATRI's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: ATRI had negative earnings growth (-11.1%) over the past year, making it difficult to compare to the Medical Equipment industry average (36.1%).


Return on Equity

High ROE: ATRI's Return on Equity (13%) is considered low.


Financial Health

How is Atrion's financial position?


Financial Position Analysis

Short Term Liabilities: ATRI's short term assets ($125.8M) exceed its short term liabilities ($12.7M).

Long Term Liabilities: ATRI's short term assets ($125.8M) exceed its long term liabilities ($14.2M).


Debt to Equity History and Analysis

Debt Level: ATRI is debt free.

Reducing Debt: ATRI has not had any debt for past 5 years.

Debt Coverage: ATRI has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: ATRI has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Atrion current dividend yield, its reliability and sustainability?

1.09%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: ATRI's dividend (1.1%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.28%).

High Dividend: ATRI's dividend (1.1%) is low compared to the top 25% of dividend payers in the US market (3.48%).


Stability and Growth of Payments

Stable Dividend: ATRI's dividends per share have been stable in the past 10 years.

Growing Dividend: ATRI's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (40.9%), ATRI's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

23.8yrs

Average board tenure


CEO

David Battat (51 yo)

10.42yrs

Tenure

US$2,065,635

Compensation

Mr. David A. Battat has been the Chief Executive Officer of ATRION Corp. since May 26, 2011 and has been its President since May 2011. Mr. Battat has been the President of Halkey-Roberts Corporation, a sub...


CEO Compensation Analysis

Compensation vs Market: David's total compensation ($USD2.07M) is below average for companies of similar size in the US market ($USD3.49M).

Compensation vs Earnings: David's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Board Members

Experienced Board: ATRI's board of directors are seasoned and experienced ( 23.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Atrion Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Atrion Corporation
  • Ticker: ATRI
  • Exchange: NasdaqGS
  • Founded: 1944
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$1.285b
  • Shares outstanding: 1.80m
  • Website: https://www.atrioncorp.com

Number of Employees


Location

  • Atrion Corporation
  • One Allentown Parkway
  • Allen
  • Texas
  • 75002-4211
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/26 22:31
End of Day Share Price2021/10/26 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.